Evidence map›Paper›PMID 40021711›Full record

ArticleScientific reports2025

Establishment of an α-thalassemia mouse model through fetal liver cell transplantation and analysis of hematological parameters.

Xin Xu, Wencheng Fu, Wenrui Ye

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Xin Xu *Shanghai Pharma Rare Disease Medicine Co., Ltd., Shanghai, 200000, China.
Wencheng Fu *Shanghai Pharma Rare Disease Medicine Co., Ltd., Shanghai, 200000, China.
Wenrui YeShanghai Pharma Rare Disease Medicine Co., Ltd., Shanghai, 200000, China. yewenrui@sphchina.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Clinically, α-thalassemia is stratified into mild, intermediate, and severe forms, differentiated by the degree of anemia severity. Specifically, severe α-thalassemia manifests in homozygous individuals, characterized by a profound α globin deficit. The presence of two α0 alleles, resulting in a complete four-gene defect (α

Indexed as

alpha-ThalassemiaLiveralpha-GlobinsAnimalsDisease Models, AnimalFemaleMiceMice, Inbred C57BLMice, Knockoutalpha-GlobinsFetal liver cells transplantationHbH inclusion bodiesHematological parametersMCHMCHCΑthalassemia mouse model

Identifiers

PMID40021711
PMCPMC11871313

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.